Graham D. Neil
Finanzdirektor/CFO bei HealthHub Patient Engagement Solutions, Inc.
Aktive Positionen von Graham D. Neil
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
HealthHub Patient Engagement Solutions, Inc.
HealthHub Patient Engagement Solutions, Inc. Specialty TelecommunicationsCommunications HealthHub Patient Engagement Solutions provides interactive patient entertainment systems. It directly involves in the design and development of interactive patient entertainment systems, including TV and phone rental systems, automated closed circuit education delivery systems, and new flat screen LCD TV products. The company was founded by Alan Arthur Simpson in 1967 and is headquartered in Regina, Canada. | Finanzdirektor/CFO | 01.06.2022 | - |
Vorstandsvorsitzender | 01.02.2022 | 01.06.2022 |
Karriereverlauf von Graham D. Neil
Ehemalige bekannte Positionen von Graham D. Neil
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
INTELLIPHARMACEUTICS INTERNATIONAL INC. | Verwaltungsdirektor | 17.12.2009 | 15.02.2010 |
Finanzdirektor/CFO | 17.12.2009 | 26.11.2010 | |
Public Communications Contact | 17.12.2009 | 26.11.2010 | |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Finanzdirektor/CFO | 01.01.1999 | 14.07.2009 |
Statistik
International
Kanada | 4 |
Operativ
Director of Finance/CFO | 3 |
Chief Administrative Officer | 1 |
Public Communications Contact | 1 |
Sektoral
Health Technology | 3 |
Communications | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
INTELLIPHARMACEUTICS INTERNATIONAL INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
HealthHub Patient Engagement Solutions, Inc.
HealthHub Patient Engagement Solutions, Inc. Specialty TelecommunicationsCommunications HealthHub Patient Engagement Solutions provides interactive patient entertainment systems. It directly involves in the design and development of interactive patient entertainment systems, including TV and phone rental systems, automated closed circuit education delivery systems, and new flat screen LCD TV products. The company was founded by Alan Arthur Simpson in 1967 and is headquartered in Regina, Canada. | Communications |
- Börse
- Insiders
- Graham D. Neil
- Erfahrung